Associated tags: Medicine, Allergy, Survival, KIT, Inflammation, SAN, Pharmaceutical industry, R, D, Research, G&A, Patient
Locations: CAMBRIDGE, MA, US, MASSACHUSETTS, MAD
Internal medicine,
Boston Children's Hospital,
Harvard Medical School,
Swedish Orphan Biovitrum,
Massachusetts General Hospital,
Genzyme,
Patient,
SAN,
Inflammation,
Senior,
Pediatrics,
KIT,
Hospital,
Medicine,
Management SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.
Key Points:
- SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.
- Prior to this role, he served as the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 to 2017.
- at Harvard Medical School and completed residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children's Hospital.
- “I am excited to join the exceptional team at Third Harmonic Bio in working to expand the treatment landscape for mast cell disorders.”
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.
- Third Harmonic Bio has a strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023, and continues to be managed in a capital efficient manner.
- R&D expenses for the year ended December 31, 2023 decreased to $24.0 million, from $24.4 million for the same period in 2022.
- G&A expenses for the year ended December 31, 2023 increased to $20.0 million, from $13.3 million for the same period in 2022.
Retrieved on:
Monday, February 26, 2024
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m.
Key Points:
- SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m.
- ET.
- A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website.
- An archived replay will be accessible for 90 days following the event.
Retrieved on:
Thursday, January 4, 2024
Marketing,
Toxicology,
Partnership,
Amgen,
IND,
Teprotumumab,
Inflammation,
KIT,
Graves' ophthalmopathy,
SAN,
Therapy,
Horizon,
Medicine,
Management SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business development, commercial operations, corporate strategy and investment banking in the biopharmaceutical industry to the company’s leadership team. In his role, Chris will be responsible for strategic leadership and direction of the company’s finance, corporate strategy, and business development functions.
Key Points:
- Chris brings extensive experience in business development, commercial operations, corporate strategy and investment banking in the biopharmaceutical industry to the company’s leadership team.
- In his role, Chris will be responsible for strategic leadership and direction of the company’s finance, corporate strategy, and business development functions.
- In business development, Chris was most recently Group Vice President, where he oversaw a number of strategic transactions and integrations.
- The company maintains a strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023.
Retrieved on:
Thursday, November 9, 2023
Molecule,
Research,
KIT,
IND,
Journal of the European Academy of Dermatology and Venereology,
G&A,
Inflammation,
MAD,
Cold urticaria,
R,
Pharmacokinetics,
European Academy of Management,
Medicine,
Venereology,
Safety,
D,
SAN,
Pharmaceutical industry,
Cryptocurrency,
Patient,
Dermatology SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the third quarter ended September 30, 2023.
Key Points:
- On October 31, 2023, Third Harmonic Bio announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor effective November 1, 2023.
- Additionally, the company announced that Robert Ho, Chief Financial Officer, is departing the organization on November 10, 2023.
- R&D expenses for the nine months ended September 30, 2023 increased to $18.0 million, from $15.1 million for the same period in 2022.
- G&A expenses for the nine months ended September 30, 2023 increased to $15.5 million, from $9.0 million for the same period in 2022.
Retrieved on:
Tuesday, October 31, 2023
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023.
Key Points:
- SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023.
- In his new role, Dr. Ray will continue support the company’s Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of 2024.
- Additionally, the company announced that Robert Ho, Chief Financial Officer, will depart the organization on November 10, 2023.
- “On behalf of Third Harmonic Bio, I would like to thank Adrian and Bob for their contributions to the company, including Adrian’s scientific expertise in our efforts to rapidly identify our new development candidate, THB335, and Bob’s support in capitalizing the company during our initial public offering, which is reflected today in our strong cash position,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio.
Retrieved on:
Thursday, August 31, 2023
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m.
Key Points:
- SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m.
- ET.
- A live audio webcast will be available within the Investors and Media section of the Third Harmonic Bio website.
- An archived replay will be accessible for 90 days following the event.
Retrieved on:
Thursday, August 10, 2023
Biochemistry,
G&A,
Medicine,
Research,
Hepatotoxicity,
KIT,
Inflammation,
Patient,
Risk,
SAN,
Liver,
R,
D,
Pharmaceutical industry SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the second quarter ended June 30, 2023.
Key Points:
- Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile
SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the second quarter ended June 30, 2023.
- The results demonstrated evidence of clinical benefit in four of the five patients, achieving partial or complete responses despite early termination of the trial.
- R&D expenses for the six months ended June 30, 2023 increased to $12.1 million, from $10.4 million for the same period in 2022.
- G&A expenses for the six months ended June 30, 2023 increased to $10.6 million, from $5.2 million for the same period in 2022.
Hepatotoxicity,
Temperature,
Biochemistry,
AE,
Serum,
Human,
Aes,
Pharmacokinetics,
Medicine,
KIT,
Inflammation,
Patient,
Risk,
SAN,
Liver,
Safety,
Pharmaceutical industry,
Dietary supplement,
CSF1R SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced its next-generation product candidate, THB335, a potent, highly selective oral small molecule KIT inhibitor with a meaningfully differentiated product profile as compared to the company’s first-generation product candidate THB001. Third Harmonic plans to file a U.S. IND and initiate clinical development of THB335 for the treatment of mast cell-mediated inflammatory diseases during the first half of 2024.
Key Points:
- THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile
Extensive nonclinical studies of THB001 identified a potential mechanistic basis for observed hepatotoxicity; structural modifications introduced in THB335 believed to address this risk
SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced its next-generation product candidate, THB335, a potent, highly selective oral small molecule KIT inhibitor with a meaningfully differentiated product profile as compared to the company’s first-generation product candidate THB001.
- Structural modifications introduced into THB335 are believed to address this risk and studies conducted to date support its differentiated metabolic profile.
- THB335, the company’s next-generation oral small molecule wild-type KIT inhibitor product candidate, retains the potency and selectivity profile of THB001, with structural modifications which are expected to mitigate the hepatoxicity risk as well as provide a differentiated metabolic, distribution and physiochemical profile.
- As previously reported, Third Harmonic Bio had $282.2 million in cash and cash equivalents as of March 31, 2023.
SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the first quarter ended March 31, 2023.
Key Points:
- SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the first quarter ended March 31, 2023.
- “We are pleased with our progress on our next generation oral KIT inhibitor program, and plan to announce our new development candidate this year,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio.
- Cash Position: Cash and cash equivalents totaled $282.2 million as of March 31, 2023.
- R&D Expenses: Research and development (R&D) expenses for the three months ended March 31, 2023 increased to $6.7 million from $6.2 million for the same period in 2022.
